Vaginal transmission of cancer from mothers with cervical cancer to infants

Ayumu Arakawa; Hitoshi Ichikawa; Takashi Kubo; Noriko Motoi; Tadashi Kumamoto; Miho Nakajima; Kan Yonemori; Emi Noguchi; Kuniko Sunami; Kouya Shiraishi; Hiroki Kakishima; Hiroshi Yoshida; Tomoro Hishiki; Naonori Kawakubo; Takafumi Kuroda; Takako Kiyokawa; Kyosuke Yamada; Nozomu Yanaihara; Kazuaki Takahashi; Aikou Okamoto; Shinsuke Hirabayashi; Daisuke Hasegawa; Atsushi Manabe; Kentaro Ono; Masaki Matsuoka; Yasuhito Arai; Yosuke Togashi; Tatsuhiro Shibata; Hiroyoshi Nishikawa; Kazunori Aoki; Noboru Yamamoto; Takashi Kohno; Chitose Ogawa

doi:10.1056/NEJMoa2030391

Vaginal transmission of cancer from mothers with cervical cancer to infants

Ayumu Arakawa, Hitoshi Ichikawa, Takashi Kubo, Noriko Motoi, Tadashi Kumamoto, Miho Nakajima, Kan Yonemori, Emi Noguchi, Kuniko Sunami, Kouya Shiraishi, Hiroki Kakishima, Hiroshi Yoshida, Tomoro Hishiki, Naonori Kawakubo, Takafumi Kuroda, Takako Kiyokawa, Kyosuke Yamada, Nozomu Yanaihara, Kazuaki Takahashi, Aikou OkamotoShinsuke Hirabayashi, Daisuke Hasegawa, Atsushi Manabe, Kentaro Ono, Masaki Matsuoka, Yasuhito Arai, Yosuke Togashi, Tatsuhiro Shibata, Hiroyoshi Nishikawa, Kazunori Aoki, Noboru Yamamoto, Takashi Kohno, Chitose Ogawa

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

26 被引用数 (Scopus)

抄録

Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.)

本文言語	英語
ページ（範囲）	42-50
ページ数	9
ジャーナル	New England Journal of Medicine
巻	384
号	1
DOI	https://doi.org/10.1056/NEJMoa2030391
出版ステータス	出版済み - 1月 7 2021
外部発表	はい

!!!All Science Journal Classification (ASJC) codes

医学（全般）

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1056/NEJMoa2030391

他のファイルとリンク

引用スタイル

Arakawa, A., Ichikawa, H., Kubo, T., Motoi, N., Kumamoto, T., Nakajima, M., Yonemori, K., Noguchi, E., Sunami, K., Shiraishi, K., Kakishima, H., Yoshida, H., Hishiki, T., Kawakubo, N., Kuroda, T., Kiyokawa, T., Yamada, K., Yanaihara, N., Takahashi, K., ... Ogawa, C. (2021). Vaginal transmission of cancer from mothers with cervical cancer to infants. New England Journal of Medicine, 384(1), 42-50. https://doi.org/10.1056/NEJMoa2030391

Arakawa, A, Ichikawa, H, Kubo, T, Motoi, N, Kumamoto, T, Nakajima, M, Yonemori, K, Noguchi, E, Sunami, K, Shiraishi, K, Kakishima, H, Yoshida, H, Hishiki, T, Kawakubo, N, Kuroda, T, Kiyokawa, T, Yamada, K, Yanaihara, N, Takahashi, K, Okamoto, A, Hirabayashi, S, Hasegawa, D, Manabe, A, Ono, K, Matsuoka, M, Arai, Y, Togashi, Y, Shibata, T, Nishikawa, H, Aoki, K, Yamamoto, N, Kohno, T & Ogawa, C 2021, 'Vaginal transmission of cancer from mothers with cervical cancer to infants', New England Journal of Medicine, vol. 384, no. 1, pp. 42-50. https://doi.org/10.1056/NEJMoa2030391

@article{6d0f728ab92d4bd793dd02e9162d2e0e,

title = "Vaginal transmission of cancer from mothers with cervical cancer to infants",

abstract = "Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.)",

author = "Ayumu Arakawa and Hitoshi Ichikawa and Takashi Kubo and Noriko Motoi and Tadashi Kumamoto and Miho Nakajima and Kan Yonemori and Emi Noguchi and Kuniko Sunami and Kouya Shiraishi and Hiroki Kakishima and Hiroshi Yoshida and Tomoro Hishiki and Naonori Kawakubo and Takafumi Kuroda and Takako Kiyokawa and Kyosuke Yamada and Nozomu Yanaihara and Kazuaki Takahashi and Aikou Okamoto and Shinsuke Hirabayashi and Daisuke Hasegawa and Atsushi Manabe and Kentaro Ono and Masaki Matsuoka and Yasuhito Arai and Yosuke Togashi and Tatsuhiro Shibata and Hiroyoshi Nishikawa and Kazunori Aoki and Noboru Yamamoto and Takashi Kohno and Chitose Ogawa",

note = "Funding Information: Supported by grants-in-aid (JP19lk1403003, JP18kk0205004, and JP20kk0205012) from the Japan Agency for Medical Research and Development, grants-in-aid (31-A-12, 30-A-6, and National Cancer Center Biobank) from the National Cancer Center Research and Development Fund, grants-in-aid for scientific research (JP18K07036) from the Ministry of Education, Culture, Sports, Science and Technology, and funding for the Phase 1 Trial of Nivolumab for Japanese Pediatric Patients with Relapsed or Refractory Solid Tumors from Ono Pharmaceutical. Publisher Copyright: Copyright {\textcopyright} 2021 Massachusetts Medical Society.",

year = "2021",

month = jan,

day = "7",

doi = "10.1056/NEJMoa2030391",

language = "English",

volume = "384",

pages = "42--50",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "1",

}

TY - JOUR

T1 - Vaginal transmission of cancer from mothers with cervical cancer to infants

AU - Arakawa, Ayumu

AU - Ichikawa, Hitoshi

AU - Kubo, Takashi

AU - Motoi, Noriko

AU - Kumamoto, Tadashi

AU - Nakajima, Miho

AU - Yonemori, Kan

AU - Noguchi, Emi

AU - Sunami, Kuniko

AU - Shiraishi, Kouya

AU - Kakishima, Hiroki

AU - Yoshida, Hiroshi

AU - Hishiki, Tomoro

AU - Kawakubo, Naonori

AU - Kuroda, Takafumi

AU - Kiyokawa, Takako

AU - Yamada, Kyosuke

AU - Yanaihara, Nozomu

AU - Takahashi, Kazuaki

AU - Okamoto, Aikou

AU - Hirabayashi, Shinsuke

AU - Hasegawa, Daisuke

AU - Manabe, Atsushi

AU - Ono, Kentaro

AU - Matsuoka, Masaki

AU - Arai, Yasuhito

AU - Togashi, Yosuke

AU - Shibata, Tatsuhiro

AU - Nishikawa, Hiroyoshi

AU - Aoki, Kazunori

AU - Yamamoto, Noboru

AU - Kohno, Takashi

AU - Ogawa, Chitose

N1 - Funding Information: Supported by grants-in-aid (JP19lk1403003, JP18kk0205004, and JP20kk0205012) from the Japan Agency for Medical Research and Development, grants-in-aid (31-A-12, 30-A-6, and National Cancer Center Biobank) from the National Cancer Center Research and Development Fund, grants-in-aid for scientific research (JP18K07036) from the Ministry of Education, Culture, Sports, Science and Technology, and funding for the Phase 1 Trial of Nivolumab for Japanese Pediatric Patients with Relapsed or Refractory Solid Tumors from Ono Pharmaceutical. Publisher Copyright: Copyright © 2021 Massachusetts Medical Society.

PY - 2021/1/7

Y1 - 2021/1/7

N2 - Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.)

AB - Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission of uterine cervical tumors were incidentally detected during routine next-generation sequencing of paired samples of tumor and normal tissue. Spontaneous regression of some lesions in the first child and slow growth of the tumor mass in the second child suggested the existence of alloimmune responses against the transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong regression of all remaining tumors in the first child. (Funded by the Japan Agency for Medical Research and Development and others; TOP-GEAR UMIN Clinical Trials Registry number, UMIN000011141.)

UR - http://www.scopus.com/inward/record.url?scp=85099166039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099166039&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa2030391

DO - 10.1056/NEJMoa2030391

M3 - Article

C2 - 33406329

AN - SCOPUS:85099166039

SN - 0028-4793

VL - 384

SP - 42

EP - 50

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 1

ER -

Vaginal transmission of cancer from mothers with cervical cancer to infants

抄録

!!!All Science Journal Classification (ASJC) codes

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル